Summary: More than two dozen mainstream media outlets are expanding psychedelic education by highlighting the research results from the first MAPS-sponsored Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), which follows the announcement published this week by The New York Times.
“Mental health experts told the [New York] Times that the study could lead to more studies on MDMA’s ability to treat other mental illnesses and on other psychedelics’ ability to treat other diseases.” —The Hill
“As is widely known, MDMA boosts serotonin, oxytocin, and dopamine to create feelings of euphoria, empathy, trust, and compassion; in a therapeutic context, it also seems capable of re-opening what neuroscientists call the “critical period” — a moment in childhood where the brain is capable of making and storing new memories.” —Rolling Stone
“Mental health experts also expressed hope that this first Phase 3 trial on psychedelic-assisted therapy could pave the way for research on other banned psychedelics — including LSD, mescaline, and psilocybin (mushrooms) — or the use of MDMA on other intractable mental health conditions.” —The Week Magazine
“Assuming it happens, FDA approval of MDMA-assisted therapy for PTSD could free researchers to fully explore these substances’ potential for providing the relief that those who live with hard-to-treat mental illnesses need and deserve.” —Mic
“This is an important study because it’s the largest study done to date, with results that—similar to previous smaller studies—are encouraging.” —Psychology Today